Cancer cells move around the body (become metastatic) by chopping up the dense matrix that surrounds them. But drugs that prevent the chopping have been disapointing in animal and human anti-cancer trials. Now researchers provide an explanation for this failure: the drug-treated cells revert to a primordial, ameboid form of cell movement that allows them to squeeze through gaps in the matrix.

Peter Friedl (University of Wuerzburg, Germany) and colleagues report in the January 20 issue of The Journal of Cell Biology that cancer cells moving through a protein matrix leave a path of destruction behind them. But when that destruction is prevented, the cells still move at a rapid rate by reverting to a more rounded, ameboid shape that is distorted as the cells squeeze through any available gaps.

This type of migration could serve as a "salvage" pathway, allowing tumor cells to take a step backward in evolutionary time to continue migrating in the presence of inhibitors. Drugs that attack both migration pathways should have a better chance of being effective against the spread of cancer.

'"/>

Contact: Lynette Henry
212-327-7938
Journal of Experimental Medicine
20-Jan-2003

Page: 1
Related biology news :

1. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
2. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
3. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
4. Cancer gene MYC emerging as key research target
5. Cancer patient, heal thyself
6. USC researcher named General Motors Cancer Research Scholar
7. Fox Chase Cancer Centers Alfred Knudson Jr. named 2004 Kyoto Prize winner
8. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
9. Cancer drug resistance research leads to possible therapeutic target for Alzheimers disease
10. Fox Chase Cancer Center research shows kidney cancer can be diagnosed in urine
11. National Cancer Gene Therapy Foundation gives $4.0 million in research grants